Inhibitors of cyclin-dependent kinase 7 (cdk7)
US-2017174692-A1 · Jun 22, 2017 · US
Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10059690B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10059690-B2 |
| Application number | US-201715799661-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2017 |
| Priority date | Apr 4, 2014 |
| Publication date | Aug 28, 2018 |
| Grant date | Aug 28, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of formula 2. A pharmaceutically acceptable salt of a compound of formula 3. The pharmaceutically acceptable salt of claim 2 , wherein the salt is a hydrochloric acid salt. 4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 4 , wherein the composition comprises the pharmaceutically acceptable salt of the compound. 6. The pharmaceutical composition of claim 5 , wherein the pharmaceutically acceptable salt is a hydrochloric acid salt. 7. The pharmaceutical composition of claim 4 , wherein the composition is a lyophilized solid. 8. The pharmaceutical composition of claim 4 , wherein the composition is an aqueous solution. 9. The pharmaceutical composition of claim 4 , wherein the composition is formulated for parenteral administration. 10. The pharmaceutical composition of claim 9 , wherein the composition is formulated for infusion. 11. The pharmaceutical composition of claim 4 , wherein the composition is in a single unit dosage form. 12. The pharmaceutical composition of claim 5 , wherein the composition is an aqueous solution. 13. The pharmaceutical composition of claim 5 , wherein the composition is formulated for parenteral administration. 14. The pharmaceutical composition of claim 13 , wherein the composition is formulated for infusion. 15. The pharmaceutical composition of claim 5 , wherein the composition is in a single unit dosage form. 16. The pharmaceutical composition of claim 6 , wherein the composition is an aqueous solution. 17. The pharmaceutical composition of claim 6 , wherein the composition is formulated for parenteral administration. 18. The pharmaceutical composition of claim 17 , wherein the composition is formulated for infusion. 19. The pharmaceutical composition of claim 6 , wherein the composition is in a single unit dosage form.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Spiro-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10059690B2 cover?
- The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multip…
- Who is the assignee on this patent?
- Syros Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).